Oseltamivir resistance during treatment of influenza A (H5N1) infection.
By Menno D. de Jong, T. T. Tran, H. K. Truong, M. H. Vo, Gavin J D Smith, V. Nguyen, V. C. Bach, T. Phan, Quang Ha Do, Yi Guan and 3 more. New England Journal of Medicine, 2005
939 citations recorded by the source corpus.
Subfields: Epidemiology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/2bd85f631dd984d965e2ce7f3a087214e2efda78
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “been susceptible to the neuraminidase inhibitors oseltamivir and zanamivir and resistant to the adamantanes (amantidine and rimantidine) [262, 263].”
- Antiviral agents active against influenza A viruses (2006, background): “Although the H274Y mutation in influenza A (H1N1) neuraminidase had been previously reported 49, 50 , its occurrence in influenza A (H5N1) infection raised concern as it was associated with death in two of the eight influenza A (H5N1)-infected patients 51 .”
- Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists (2015, background): “infection but has given rise to drug-resistant mutants (2, 3).”